Assessing the Measure of a New Drug: Is Survival the Only Thing That Matters?
- 20 April 2008
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (12), 1922-1923
- https://doi.org/10.1200/jco.2007.14.8064
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Evaluation of Tumor Response, Disease Control, Progression-Free Survival, and Time to Progression As Potential Surrogate End Points in Metastatic Breast CancerJournal of Clinical Oncology, 2008
- The impact of new chemotherapeutic and hormone agents on survival in a population‐based cohort of women with metastatic breast cancerCancer, 2007
- Title PageCurrent Problems in Cancer, 2006
- Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast CancerThe New England Journal of Medicine, 2005
- Design Issues of Randomized Phase II Trials and a Proposal for Phase II Screening TrialsJournal of Clinical Oncology, 2005
- Objective Response to Chemotherapy As a Potential Surrogate End Point of Survival in Metastatic Breast Cancer PatientsJournal of Clinical Oncology, 2005
- Evaluating the Efficiency of Targeted Designs for Randomized Clinical TrialsClinical Cancer Research, 2004
- Bayesian Statistics and the Efficiency and Ethics of Clinical TrialsStatistical Science, 2004
- Surrogate End Points in Clinical Trials: Are We Being Misled?Annals of Internal Medicine, 1996
- Surrogate endpoints in clinical trials: Definition and operational criteriaStatistics in Medicine, 1989